Boston Trust Walden Corp Buys 16,045 Shares of Edwards Lifesciences Corporation $EW

Boston Trust Walden Corp increased its position in Edwards Lifesciences Corporation (NYSE:EW) by 6.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 282,950 shares of the medical research company’s stock after purchasing an additional 16,045 shares during the quarter. Boston Trust Walden Corp’s holdings in Edwards Lifesciences were worth $22,659,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in EW. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the first quarter worth about $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter valued at about $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter valued at about $26,000. Kemnay Advisory Services Inc. purchased a new position in shares of Edwards Lifesciences during the fourth quarter valued at approximately $27,000. Finally, Kohmann Bosshard Financial Services LLC purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $28,000. 79.46% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research note on Monday, April 20th. Mizuho set a $95.00 price objective on Edwards Lifesciences and gave the stock an “outperform” rating in a research report on Monday, April 13th. TD Cowen restated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a research note on Tuesday, June 2nd. Truist Financial set a $90.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, April 24th. Finally, Canaccord Genuity Group set a $85.00 price target on shares of Edwards Lifesciences and gave the stock a “hold” rating in a report on Friday, April 24th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences presently has an average rating of “Moderate Buy” and an average price target of $96.39.

Edwards Lifesciences Stock Down 0.1%

Shares of NYSE EW opened at $94.31 on Friday. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06. The company has a market cap of $54.31 billion, a P/E ratio of 50.17, a P/E/G ratio of 2.37 and a beta of 0.86. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $94.47. The business has a 50-day simple moving average of $85.61 and a two-hundred day simple moving average of $83.57.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.73 by $0.05. The firm had revenue of $1.65 billion for the quarter, compared to the consensus estimate of $1.60 billion. Edwards Lifesciences had a net margin of 17.39% and a return on equity of 15.19%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. Research analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Activity

In related news, VP Daniel J. Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $83.01, for a total transaction of $84,587.19. Following the completion of the transaction, the vice president directly owned 33,934 shares in the company, valued at $2,816,861.34. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction dated Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 58,977 shares of company stock valued at $4,921,803 over the last 90 days. Company insiders own 0.31% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.